ImmuPharma (IMMX)

Last close As at 06/02/2026

0.00 (0.00%)

Market capitalisation

ImmuPharma is a UK drug development company linked to the leading French research organisation (CNRS). The lead project, Lupuzor, is in a Phase IIb trial with partner Cephalon for lupus. A new peptide cancer product, Nucant-6L, has entered Phase I/II studies.